Navigation Links
Soligenix Announces Private Equity Financing of $5.16 Million With Its Partner Sigma-Tau and Other Institutional Investors
Date:6/16/2010

PRINCETON, N.J., June 16 /PRNewswire-FirstCall/ -- Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced today that it has entered into common stock purchase agreements with both existing and new investors totaling approximately $5.16 million. Soligenix's North American commercial partner, Sigma-Tau Pharmaceuticals, Inc., participated in this financing.

Upon closing of the private placement, Soligenix will issue approximately 25,178,180 shares of common stock and warrants to purchase up to approximately 15,106,910 shares of Soligenix common stock for an aggregate price of approximately $5.16 million. The expiration date of the warrants will be accelerated if the Company's common stock meets certain price thresholds and Soligenix would receive additional gross proceeds of approximately $4.23 million if all are exercised. National Securities Corporation and Griffin Securities, Inc. served as co-placement agents on the financing.

"We are pleased with this vote of confidence and continued support from our partner Sigma-Tau and the institutional investors in what are obviously challenging market conditions," stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. "With a strengthened balance sheet, our top priority remains the completion of our confirmatory Phase 3 trial of orBec® in the treatment of acute GI GVHD, an important unmet medical need."

The Company's common stock will be sold to accredited investors in a private placement in reliance on an exemption from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"). The shares will
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol SNGX
2. Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors
3. Soligenix to Present at 8th Annual BIO Investor Forum
4. Soligenix to Present at 12th Annual BIO CEO & Investor Conference
5. Soligenix Reports Third Quarter 2009 Financial Results
6. Soligenix Announces Grant of Broad European Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
7. Soligenix Announces Completion of Patient Enrollment in Phase 2 Acute GVHD Prevention Clinical Trial
8. Soligenix Reports First Quarter 2010 Financial Results and Reviews Accomplishments
9. Soligenix Announces Grant of US Patent for the Treatment of Irritable Bowel Syndrome with Oral Beclomethasone Dipropionate
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... March 27, 2015 WuXi PharmaTech (Cayman) ... R&D capability and technology platform company serving the ... today that an Investigational New Drug (IND) application ... rheumatoid arthritis has been accepted for review by ... In September 2012, MedImmune, the global ...
(Date:3/26/2015)... SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; ... including the appointment of auditors, its annual and special ... "Meeting") was adjourned, as previously disclosed on March 25, ... Toronto time). The date of the ... The Meeting will reconvene at the offices of the ...
(Date:3/26/2015)... BOSTON , March 26, 2015 /PRNewswire/ ... ), a global clinical research organization ... signed a definitive agreement to acquire all ... India ("QSI"), a leading provider of specialized ... refers to the collection, detection, assessment, monitoring, ...
(Date:3/25/2015)... pharmaceutical market is one of the most ... its absolute size, plus a growing economy and increasing ... Business Monitor International. The Russian market is set to ... market, with growth estimates around 10-15% annually reaching an ... About Green Cross Green Cross provides ...
Breaking Biology Technology:Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 3SQI Diagnostics Inc. Announces Adjournment of Meeting 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4
... SAN DIEGO, March 25 ADVENTRX Pharmaceuticals, Inc. (NYSE ... for the fourth quarter and year ended December 31, ... we advanced a new business model focused on lower-risk ... our new lead programs, but given the difficult economic ...
... RICHMOND, Va., March 25 Insmed Inc. (Nasdaq: ... today announced that on Monday, March 23, 2009, NASDAQ issued ... a minimum $1 closing bid price and those rules requiring ... The suspension will remain in effect through Friday, July 17, ...
... - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ... enrolment in its U.K. clinical trial to evaluate ... in combination with gemcitabine (Gemzar(R)) in patients with ... The principal investigators are Dr. Johann de Bono ...
Cached Biology Technology:ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 2ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 3ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 4ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 5ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 6ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 7Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule 2Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial 2Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial 3
(Date:3/24/2015)... March 24, 2015   NexID Biometrics LLC, ... security-authentication needs, today announced the beginning of shipments of ... The company, based in Potsdam, ... three-day Connect:ID Expo, which began here today at the ... version 2.0 of its SDK boosts the accuracy rate ...
(Date:3/23/2015)... BOSTON, Mass , March 23, 2015 SoundView ... shipment of NXT-ID,s (NASDAQ: NXTD ) Wocket smart wallet. SoundView ... world user feedback on their experience with the Wocket in ... experience at CVS, Whole Foods and other retailers, making both ... Kris Tuttle also says, "If the company meets ...
(Date:3/23/2015)... , March 23, 2015  In the 2014 fiscal ... case conviction losses. This figure accounts for a fraction ... to The Nilson Report, exceeds $11 billion globally. The ... after a crime has occurred. Investor Mark Saint ... expert Joe Paolella partnered to administer the ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... come out of research conducted on the edge of ... Olduvai Gorge in Tanzania since that produced by Louis ... a special issue of the prestigious Journal of ... of the Bernard Price Institute for Palaeontological Research, and ...
... on a unique vertebrate called the sea lamprey shows that ... development. These genes are paradoxically lost all throughout the developing ... or PGCs. The PGCs can be thought of as embryonic ... generation of lampreys. Based on computational analysis, a significant number ...
... rapidly create healthy clots and nearly double the survival ... research shows. "We knew an injection of these ... bleeding is stopped in time to increase survival following ... at Case Western Reserve University and leader of the ...
Cached Biology News:Dawn of humanity illuminated in special journal edition - 50 years after the Leakeys 2Research reveals unique solution to gene regulation 2Nanoparticles added to platelets double internal injury survival rate 2
Request Info...
... 2 , Maintenance 112 days/each ... , Immunizations/Boost injections x5 /each ... /each , Production bleed (25 ml ... Bleed ~ 100 ml blood (~50 ml serum) x1 ...
FluoSpheres® biotin-labeled microspheres, 1.0 µm, yellow-green fluorescent (505/515) *1% solids*...
chk 1 kinase...
Biology Products: